



- Bioassays are critical to all stages of product development;
 listen to them!
- Bioassay scientists & statisticians can achieve powerful
 outcomes when working together to analyze and transform
 complex data into meaningful potency results.
- Developing MOA-relevant, QC-friendly bioassays for emerging biologic and vaccine modalities requires new analytical tools and critical thinking about how we describe product potency.
- Emerging from the COVID-19 pandemic, industry and regulatory authorities are poised to bring medicines to patients faster than ever before!

BIOASSAYS 2023 BY THE NUMBERS



First-Time Attendees

78



Speaker/Panelist
Participation

20



Company Representation

54



Country Collaboration

10

Canada | Denmark | Germany | Hungary | Israel | Japan | Sweden | Switzerland | United Kingdom | United States



